Patient-reported outcomes from a phase 2 PLATINUM trial of nivolumab combination therapy sparing concurrent cisplatin in nasopharyngeal carcinoma

Key Points

The aim is to evaluate the patient-reported outcomes from the nivolumab combination therapy in nasopharyngeal carcinoma while avoiding cisplatin.
Conducted a phase 2 trial focusing on nivolumab and its effects.
Enrolled patients diagnosed with nasopharyngeal carcinoma.
Assessed patient-reported outcomes related to quality of life and treatment satisfaction.
Patients reported improved quality of life compared to traditional treatments.
Treatment was generally well tolerated without significant cisplatin-related side effects.

Phase 2 trial examines patient-reported outcomes of nivolumab therapy in nasopharyngeal carcinoma, suggesting benefits without using cisplatin.

No takes yet. Share an insight, caveat, or question.

Xu et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Share